Stephan Jackman - Jun 14, 2021 Form 3 Insider Report for Alzamend Neuro, Inc. (ALZN)

Role: Chief Executive Officer, Director
Signature: /s/ Stephan Jackman
Stock symbol: ALZN
Transactions as of: Jun 14, 2021
Transactions value $: $0
Form type: 3
Date filed: 6/14/2021, 07:55 PM
Next filing: Sep 20, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ALZN	Stock Options (right to buy)							Jun 14, 2021	Common Stock	2M	$1.50	Direct	F1
holding	ALZN	Stock Options (right to buy)							Jun 14, 2021	Common Stock	5M	$1.00	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person's right to exercise this stock option is subject to contingent vesting based upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after our initial public offering of our common stock, or (ii) stepped target prices for a change in control transaction. Of this stock option, no shares of Common Stock are currently vested and exercisable.
F2	Mr. Jackman was granted stock options (the "Options") to purchase 5,000,000 shares of the Issuer's Common Stock which Options are exercisable for a period of ten years beginning on November 16, 2018, at a per share price of $1.00, and vests as follows: (i) 3,000,000 shares of Common Stock will vest ratably over 48 months beginning on November 16, 2018; (ii) upon approval by the U.S. Food and Drug Administration ("FDA") of the New Drug Application ("NDA") for AL001, 1,000,000 shares of Common Stock will vest ratably over 36 months from November 1, 2018; and (iii) upon approval by the FDA of an NDA for AL002, 1,000,000 shares of Common Stock will vest ratably over 48 months from November 1, 2018. Of this stock option, 2,000,000 shares are currently vested and exercisable.

Content

The Reporting Person's right to exercise this stock option is subject to contingent vesting based upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after our initial public offering of our common stock, or (ii) stepped target prices for a change in control transaction. Of this stock option, no shares of Common Stock are currently vested and exercisable.

Mr. Jackman was granted stock options (the "Options") to purchase 5,000,000 shares of the Issuer's Common Stock which Options are exercisable for a period of ten years beginning on November 16, 2018, at a per share price of $1.00, and vests as follows: (i) 3,000,000 shares of Common Stock will vest ratably over 48 months beginning on November 16, 2018; (ii) upon approval by the U.S. Food and Drug Administration ("FDA") of the New Drug Application ("NDA") for AL001, 1,000,000 shares of Common Stock will vest ratably over 36 months from November 1, 2018; and (iii) upon approval by the FDA of an NDA for AL002, 1,000,000 shares of Common Stock will vest ratably over 48 months from November 1, 2018. Of this stock option, 2,000,000 shares are currently vested and exercisable.